MD20190080A2 - Forme cristaline de (s)-afoxolaner - Google Patents

Forme cristaline de (s)-afoxolaner

Info

Publication number
MD20190080A2
MD20190080A2 MDA20190080A MD20190080A MD20190080A2 MD 20190080 A2 MD20190080 A2 MD 20190080A2 MD A20190080 A MDA20190080 A MD A20190080A MD 20190080 A MD20190080 A MD 20190080A MD 20190080 A2 MD20190080 A2 MD 20190080A2
Authority
MD
Moldova
Prior art keywords
crystalline forms
afoxolaner
animal
compositions
treating
Prior art date
Application number
MDA20190080A
Other languages
English (en)
Russian (ru)
Inventor
ДЕ ВРИС Рулоф Йоханнес ГОРТЕР
Брюно БАЙОН
Силвайн ЛАФОН
ДЕ СЕН МИШЕЛЬ Мириам ГЕЙ
Стефан КОЗЛОВИЦ
Original Assignee
Boehringer Ingelheim Animal Health USA Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health USA Inc. filed Critical Boehringer Ingelheim Animal Health USA Inc.
Publication of MD20190080A2 publication Critical patent/MD20190080A2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Secondary Cells (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Prezenta invenţie se referă la forme cristaline ale compusului cu formula (Ia) şi procedee de obţinere a formelor cristaline, precum şi la compoziţii, care conţin forme cristaline, şi forme cristaline pentru tratarea sau profilaxia infecţiilor parazitare la animale.(Ia)
MDA20190080A 2017-04-05 2018-04-05 Forme cristaline de (s)-afoxolaner MD20190080A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482175P 2017-04-05 2017-04-05
PCT/US2018/026328 WO2018187623A1 (en) 2017-04-05 2018-04-05 Crystalline forms of (s)-afoxolaner

Publications (1)

Publication Number Publication Date
MD20190080A2 true MD20190080A2 (ro) 2020-04-30

Family

ID=62092252

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20190080A MD20190080A2 (ro) 2017-04-05 2018-04-05 Forme cristaline de (s)-afoxolaner

Country Status (23)

Country Link
US (2) US10662163B2 (ro)
EP (1) EP3606911A1 (ro)
JP (1) JP7222909B2 (ro)
KR (1) KR102612648B1 (ro)
CN (1) CN111032634A (ro)
AR (1) AR111412A1 (ro)
AU (1) AU2018250304B2 (ro)
BR (1) BR112019021072A2 (ro)
CA (1) CA3059114A1 (ro)
CL (1) CL2019002840A1 (ro)
CO (1) CO2019011980A2 (ro)
EA (1) EA201992360A1 (ro)
IL (1) IL269792B (ro)
MD (1) MD20190080A2 (ro)
MX (1) MX2019011931A (ro)
MY (1) MY188420A (ro)
PH (1) PH12019502277A1 (ro)
SG (1) SG11201909229SA (ro)
TW (1) TWI782976B (ro)
UA (1) UA125727C2 (ro)
UY (1) UY37665A (ro)
WO (1) WO2018187623A1 (ro)
ZA (1) ZA201906464B (ro)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018250304B2 (en) * 2017-04-05 2022-03-03 Boehringer lngelheim Vetmedica GMBH Crystalline forms of (S)-afoxolaner
WO2021254445A1 (zh) * 2020-06-19 2021-12-23 东莞市东阳光仿制药研发有限公司 一种gaba抑制剂的晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) * 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI649303B (zh) * 2007-08-17 2019-02-01 杜邦股份有限公司 製備４-乙醯基-ｎ-〔２-側氧基-２-〔（２，２，２-三氟乙基）胺基〕乙基〕-１-萘甲醯胺之化合物及方法
DK2576523T3 (en) * 2010-05-27 2016-04-18 Du Pont A crystalline form of 4- [5- [3-chloro-5- (trifluoromethyl) phenyl] -4,5-dihydro-5- (trifluoromethyl) -3-isoxazolyl] -N- [2-oxo-2 - [( 2,2,2-trifluoroethyl) amino] ethyl] - 1-naphthalenecarboxamide
BR122019001738B1 (pt) * 2011-09-12 2019-11-05 Merial Inc composições parasiticidas compreendendo um agente ativo de isoxazolina e usos das mesmas
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
JP2015028006A (ja) * 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
UY36570A (es) * 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
SG10201912724SA (en) * 2015-04-08 2020-02-27 Boehringer Ingelheim Animal Health Usa Inc Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
RS62755B1 (sr) 2016-04-06 2022-01-31 Boehringer Ingelheim Animal Health Usa Inc Postupak za pripremu enantiomerno-obogaćenih jedinjenja izoksazolina - kristalnog toluenskog solvata (s)-afoksolanera
AU2018250304B2 (en) * 2017-04-05 2022-03-03 Boehringer lngelheim Vetmedica GMBH Crystalline forms of (S)-afoxolaner

Also Published As

Publication number Publication date
UY37665A (es) 2018-10-31
UA125727C2 (uk) 2022-05-25
US10662163B2 (en) 2020-05-26
AU2018250304A1 (en) 2019-10-31
WO2018187623A1 (en) 2018-10-11
JP7222909B2 (ja) 2023-02-15
CN111032634A (zh) 2020-04-17
SG11201909229SA (en) 2019-11-28
US11130739B2 (en) 2021-09-28
US20200270219A1 (en) 2020-08-27
WO2018187623A8 (en) 2019-10-24
MY188420A (en) 2021-12-08
IL269792B (en) 2022-04-01
MX2019011931A (es) 2020-01-13
TW201841895A (zh) 2018-12-01
CL2019002840A1 (es) 2020-01-10
KR102612648B1 (ko) 2023-12-11
AU2018250304B2 (en) 2022-03-03
EA201992360A1 (ru) 2020-09-02
ZA201906464B (en) 2021-08-25
JP2020513010A (ja) 2020-04-30
IL269792A (en) 2019-11-28
KR20190136055A (ko) 2019-12-09
CA3059114A1 (en) 2018-10-11
TWI782976B (zh) 2022-11-11
CO2019011980A2 (es) 2020-02-18
EP3606911A1 (en) 2020-02-12
BR112019021072A2 (pt) 2020-05-12
PH12019502277A1 (en) 2020-09-14
AR111412A1 (es) 2019-07-10
US20180354917A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
AU2016278853A8 (en) Petrolatum-based compositions comprising cationic biocides
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2018006287A (es) Inhibidores de acc de triazol y usos de los mismos.
MX2018004344A (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
WO2015003816A3 (en) Cystobactamides
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2023002507A (es) Inhibidores de cd73.
EA201790779A1 (ru) Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений
PH12020500655A1 (en) Compounds
MX2021000189A (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias.
MX2020006191A (es) Bacteriocinas terapeuticas.
MX2018015247A (es) Heterociclos de biarilmetilo.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
TN2019000106A1 (en) Novel compounds for treating parasitic disease
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
NZ739518A (en) Compounds useful for inhibiting ror-gamma-t
MD3630136T2 (ro) Compoziții care cuprind tulpini bacteriene
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PH12018501646A1 (en) Compositions and methods for treating infections
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
PH12019502277A1 (en) Crystalline forms of (s)-afoxolaner